Currently Viewing:
Newsroom
Currently Reading
Study Investigates Treatment Trends in COPD and Asthma–COPD Overlap Patients
June 27, 2017 – Alison Rodriguez
Diagnostic Immunoassays Could Spare Patients High-Risk Pancreatic Resection
June 25, 2017 – Surabhi Dangi-Garimella, PhD
FDA Approves Rituxan Hycela for Treating Certain Blood Cancers
June 24, 2017 – Alison Rodriguez
Genentech's Ocrevus Reduces Disease Progression in Multiple Sclerosis Patients
June 23, 2017 – Alison Rodriguez
FDA Approves of Darzalex Combination for Multiple Myeloma
June 23, 2017 – Alison Rodriguez
FDA Approves Baxdela for Skin Infections
June 22, 2017 – Alison Rodriguez
What We're Reading: ACA Insurers File; Missouri Sues Opioid Manufacturers; Mylan's EpiPen Deals
June 22, 2017 – AJMC Staff
Asian Women Face Greater Barriers to Follow-up Care on Abnormal Mammogram
June 20, 2017 – Surabhi Dangi-Garimella, PhD
Analysis of COPD Hospitalization Trends Finds Gender Gap for Mortality
June 20, 2017 – AJMC Staff

Study Investigates Treatment Trends in COPD and Asthma–COPD Overlap Patients

Alison Rodriguez
While treatments prescribed for people with chronic pulmonary disease (COPD) and asthma—COPD overlap syndrome (ACOS) are similar, there is a need for a clearer therapeutic approach for patients with ACOS, according to a new study.
While treatments prescribed for people with chronic pulmonary disease (COPD) and asthma–COPD overlap syndrome (ACOS) are similar, there is a need for a clearer therapeutic approach for patients with ACOS, according to a new study published in the International Journal of Chronic Obstructive Pulmonary Disease. The research aimed to investigate the treatment trends in patients with COPD and those with ACOS while comparing the treatments between each individual disease.  

COPD and asthma are respiratory conditions that cause chronic inflammation due to bronchial obstruction. ACOS patients present symptoms of both diseases, along with continuous restricted airflow and make up 12% to 55% of all chronic obstructive airway diseases.

“Despite this considerable prevalence of ACOS, few randomized controlled trials have been performed in patients with ACOS and a clear pharmacotherapeutic approach is yet to be established for ACOS,” wrote the researchers. “Furthermore, we explored the clinical characteristics of patients with ACOS compared with an asthma-only and a COPD-only population in order to better understand these patients.”

The study included 9042 asthma patients, 7119 COPD patients, and 523 patients with ACOS, collected from the 2012 and 2013 Adelphi Respiratory Disease Specific Programmes (DSPs), a large physician and patient real-world survey. Physicians completed a report based on patient demographics, clinical characteristics, clinical management, outcomes, and treatment history and use. From this survey information, the researchers could draw an analysis of similar treatments among diseases.

The study found the most common prescribed treatments among all diagnoses were inhaled corticosteroid/long-acting beta-agonist inhalers (ICS/LABA) plus long acting muscarinic antagonist (LAMA) (1.4% asthma, 32% COPD, 30% ACOS), followed by ICS/LABA (41.5% asthma, 17% COPD, 19% ACOS), and then LAMA monotherapy (0.4% asthma, 19% COPD, 6% ACOS). Significant differences between asthma and ACOS treatments are emphasized in the study, as the data demonstrates the similarities between ACOS treatments and COPD treatments as opposed to asthma-only regimens.

Due to the lack of previous research on ACOS, this study acknowledged the specific demographics of those with ACOS. The results suggested that patients with ACOS are more likely to be female and have a higher body mass index than COPD patients. When compared to asthma patients, the ACOS participants had a higher body mass index and were more likely to be current or previous smokers.

“Identification of and knowledge regarding ACOS has improved in recent times, and definitions and treatment guidelines are now available to assist in the management of affected patients,” the authors concluded. “Further research, including well-designed clinical trials in well-defined patient groups, is needed to improve outcomes in this prognostically poor patient population.”

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up